Tags

Type your tag names separated by a space and hit enter

The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
Gynecol Endocrinol. 2005 Sep; 21(3):154-60.GE

Abstract

OBJECTIVE

The aim of the present study was to assess the effects of metformin and rosiglitazone on menstrual cyclicity and hirsutism in patients with polycystic ovary syndrome (PCOS).

MATERIALS AND METHODS

Ninety-six patients were included in the study. Serum sex steroids, serum fasting glucose and insulin levels, and insulin response to a 75-g oral glucose tolerance test were assessed in all patients. Menstrual cyclicity, with recording of menses in the 6-month periods before the study and during treatment, was evaluated in each patient. Patients were divided into two groups: one was treated with metformin (MET group, n = 48), while the other received rosiglitazone (ROSI group, n = 48). At baseline and after 24 weeks of treatment all patients underwent hormonal and clinical assessments, including body mass index (BMI), waist and hip measurements and Ferriman - Gallwey (FG) scores.

RESULTS

Of the 96 patients included in the study, 88 (91.7%) were able to complete it and yielded data for analyses. After the 24-week treatment period, fasting insulin levels and area under the curve for serum insulin decreased significantly, while the glucose/insulin ratio increased in both groups. The degree of reduction in serum free testosterone and androstenedione levels was similar in the two groups. The decreases in luteinizing hormone/follicle-stimulating hormone ratio and serum dehydroepiandrosterone sulfate levels were significantly greater in the ROSI group compared with the MET group. BMI increased in the ROSI group, while it decreased in the MET group. In patients with menstrual disturbance treated with rosiglitazone, menstrual cycles became regular in 87.8%, while improvement occurred in 79.3% of the patients treated with metformin. FG score decreased in both ROSI and MET groups, but the degree of decrease was significantly greater in the ROSI group than in the MET group.

CONCLUSION

Our data show that both metformin and rosiglitazone improve ovarian function and hirsutism in patients with PCOS. Rosiglitazone appears better than metformin in the treatment of hirsutism and has better patient tolerance.

Authors+Show Affiliations

Department of Endocrinology and Metabolism, Faculty of Medicine, Kirikkale University, Kirikkale, Turkey. murartt@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16335907

Citation

Yilmaz, Murat, et al. "The Effects of Rosiglitazone and Metformin On Menstrual Cyclicity and Hirsutism in Polycystic Ovary Syndrome." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 21, no. 3, 2005, pp. 154-60.
Yilmaz M, Karakoç A, Törüner FB, et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol. 2005;21(3):154-60.
Yilmaz, M., Karakoç, A., Törüner, F. B., Cakir, N., Tiras, B., Ayvaz, G., & Arslan, M. (2005). The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 21(3), 154-60.
Yilmaz M, et al. The Effects of Rosiglitazone and Metformin On Menstrual Cyclicity and Hirsutism in Polycystic Ovary Syndrome. Gynecol Endocrinol. 2005;21(3):154-60. PubMed PMID: 16335907.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. AU - Yilmaz,Murat, AU - Karakoç,Ayhan, AU - Törüner,Füsun B, AU - Cakir,Nuri, AU - Tiras,Bülent, AU - Ayvaz,Göksun, AU - Arslan,Metin, PY - 2005/12/13/pubmed PY - 2005/12/31/medline PY - 2005/12/13/entrez SP - 154 EP - 60 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol Endocrinol VL - 21 IS - 3 N2 - OBJECTIVE: The aim of the present study was to assess the effects of metformin and rosiglitazone on menstrual cyclicity and hirsutism in patients with polycystic ovary syndrome (PCOS). MATERIALS AND METHODS: Ninety-six patients were included in the study. Serum sex steroids, serum fasting glucose and insulin levels, and insulin response to a 75-g oral glucose tolerance test were assessed in all patients. Menstrual cyclicity, with recording of menses in the 6-month periods before the study and during treatment, was evaluated in each patient. Patients were divided into two groups: one was treated with metformin (MET group, n = 48), while the other received rosiglitazone (ROSI group, n = 48). At baseline and after 24 weeks of treatment all patients underwent hormonal and clinical assessments, including body mass index (BMI), waist and hip measurements and Ferriman - Gallwey (FG) scores. RESULTS: Of the 96 patients included in the study, 88 (91.7%) were able to complete it and yielded data for analyses. After the 24-week treatment period, fasting insulin levels and area under the curve for serum insulin decreased significantly, while the glucose/insulin ratio increased in both groups. The degree of reduction in serum free testosterone and androstenedione levels was similar in the two groups. The decreases in luteinizing hormone/follicle-stimulating hormone ratio and serum dehydroepiandrosterone sulfate levels were significantly greater in the ROSI group compared with the MET group. BMI increased in the ROSI group, while it decreased in the MET group. In patients with menstrual disturbance treated with rosiglitazone, menstrual cycles became regular in 87.8%, while improvement occurred in 79.3% of the patients treated with metformin. FG score decreased in both ROSI and MET groups, but the degree of decrease was significantly greater in the ROSI group than in the MET group. CONCLUSION: Our data show that both metformin and rosiglitazone improve ovarian function and hirsutism in patients with PCOS. Rosiglitazone appears better than metformin in the treatment of hirsutism and has better patient tolerance. SN - 0951-3590 UR - https://www.unboundmedicine.com/medline/citation/16335907/The_effects_of_rosiglitazone_and_metformin_on_menstrual_cyclicity_and_hirsutism_in_polycystic_ovary_syndrome_ L2 - https://www.tandfonline.com/doi/full/10.1080/09513590500231627 DB - PRIME DP - Unbound Medicine ER -